A new drug, lorundostat, has shown promising results in clinical trials for patients with uncontrolled high blood pressure. In a study published in the New England Journal of Medicine, lorundostat reduced systolic blood pressure by an average of 15 points, outperforming placebo treatments. Conducted on 285 patients, the findings align with earlier phase three trials. This drug, which blocks aldosterone—linked to increased blood pressure—offers a potential new solution for patients who have not responded well to existing anti-hypertensive medications. With over 120 million Americans affected by hypertension, new options are critical for effective management.
The drug lorundostat shows promise for patients with uncontrolled hypertension, averaging a 15-point reduction in systolic blood pressure compared to placebo.
Dr. Michael Wilkinson emphasizes the significance of these results, as many patients still struggle to control blood pressure despite multiple medications.
Aldosterone promotes water retention, increasing blood volume and pressure. This new drug targets that mechanism with fewer complications.
Patients with hypertension, exceeding 120 million in the U.S., need new treatment options—lorundostat could be a key addition.
Collection
[
|
...
]